News
QURE
8.50
-0.82%
-0.07
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Seeking Alpha · 3d ago
uniQure Advances with Strategic Facility Sale and Partnership Deals
TipRanks · 3d ago
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
Barchart · 3d ago
Weekly Report: what happened at QURE last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at QURE last week (0708-0712)?
Weekly Report · 07/15 09:09
What Led To A 150% Rise In uniQure Stock In A Week?
NASDAQ · 07/15 02:55
Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More
Home Stock Ideas Quick Picks & Lists Undercovered Dozen: Evergy, Navitas Semiconductor, Whirlpool And More. This edition of the 'Undercovered' Dozen highlights twelve ideas from June 28th - July 11th on stocks with limited coverage. Newmont Corporation and Teck Resources are highlighted as a pair trade in the Industrials space. Evergy faces risks in the AI data center market, but could benefit from chip proliferation.
Seeking Alpha · 07/12 19:15
More Money In The Bank For uniQure Insiders Who Divested US$533k
UniQure N.V. Insiders have sold US$533k worth of stock in the last 12 months. The biggest single sale was by Matthew Kapusta for US$177k. In the last year, uniqure insiders didn't buy any stock. The company has seen significant insider selling in the past three months. UniQures insiders own about US$8.2m worth of shares. But the company is not the best place to buy. You can see the insider transactions at uni Qure.
Simply Wall St · 07/12 13:07
Buy Rating Affirmed on uniQure Amid Promising AMT-130 Clinical Outcomes for Huntington’s Disease
UniQure's AMT-130 has shown an 80% slowing of disease progression in the Phase 1/2 study of Huntington’s disease. Analyst Joseph Schwartz has reiterated a Buy rating on uniQure and increased the price target to $26.00. Corporate insider sentiment is negative on the stock.
TipRanks · 07/12 07:15
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Conagra Brands, Inc. Shares fell 3.9% to $27.70 on Thursday. The company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below estimates. Kazia Therapeutics Limited shares surged 88.6% in the mid-day session. Biodexa Pharmaceuticals Plc shares jumped 78.6%.
Benzinga · 07/11 18:02
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
NASDAQ · 07/11 13:12
Why Are UniQure Shares Surging Today?
UniQure's AMT-130, a gene therapy targeting Huntington's disease, shows 80% reduction in disease progression in patients treated with the therapy. The company's shares are soaring following the release of promising interim data from its Phase I/II clinical trials.
Benzinga · 07/10 20:00
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
SeaStar Medical Holding Corporation shares fell 34% to $8.55 on Wednesday. Virpax Pharmaceuticals, Inc. Shares jumped 139% in the mid-day session. The company entered into a $10 million registered direct offering of shares at $10.55 per share.
Benzinga · 07/10 17:18
SMART Global Posts Upbeat Results, Joins Aehr Test Systems, MarineMax And Other Big Stocks Moving Higher On Wednesday
SMART Global Holdings, Inc. Shares jumped 17.4% to $27.27 on Wednesday. The company reported better-than-expected third-quarter financial results. The Nasdaq Composite gained around 0.4%. Shares of SMART Global rose sharply during Wednesday's session.
Benzinga · 07/10 14:48
Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
NASDAQ · 07/10 13:55
Maintaining Hold on uniQure: Promising AMT-130 Data Balanced with Regulatory and Financial Uncertainties
TipRanks · 07/10 13:36
uniQure (QURE) Soars on New Huntington's Disease Study Data
NASDAQ · 07/10 13:01
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Shares of Kura Sushi USA, Inc. Fell sharply in today's pre-market trading after the company posted downbeat results for its third quarter on Tuesday. LegalZoom.com and Stardust Power also recorded losses. The Nasdaq futures were higher on Wednesday morning.
Benzinga · 07/10 12:01
uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
NASDAQ · 07/10 09:49
Maintaining Hold on uniQure Amid Optimism and Regulatory Uncertainties for AMT-130 in HD
TipRanks · 07/10 09:16
More
Webull provides a variety of real-time QURE stock news. You can receive the latest news about Uniqure through multiple platforms. This information may help you make smarter investment decisions.
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.